When was Guardian Bio founded?

Guardian Bio was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Guardian Bio located?

Guardian Bio is headquartered in Boston, United States.

How many employees does Guardian Bio have?

As of Jan 31, 2026, the latest employee count at Guardian Bio is 3.

Is Guardian Bio a funded company?

Guardian Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on 2022.

When was the latest funding round of Guardian Bio?

Guardian Bio's latest funding was a $***** Seed round on 2022, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $870M in funding in 2026 to date.

Where does Guardian Bio rank among its competitors?

Guardian Bio ranks 1404th amongst 3239 active competitors, of which 1118 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Guardian Bio?

Guardian Bio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Moderna secured the most recent funding round in January, 2025.

Guardian Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cell-therapeutics for the treatment of cancer. It offers personalized cell therapy based on dendritic cells that will revitalize the immune system and kill cancer cells. Its products include neoantigen vaccines, oncolytic viruses, checkpoint inhibitors, and other cell therapies.

Key Metrics

Founded Year

2022

Location

Boston, United States

Stage

Seed

Total Funding

$500K in 1 round

Latest Funding Round

Seed, 2022, $*****

Investors

Y Combinator & 2 more

Ranked

1404^th among 3239 active competitors

Employee Count

3 as on Jan 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3013 more

View Guardian Bio's full profile

Guardian Bio has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on 2022 for $*****. 1 investor participated in its latest round. Guardian Bio has 3 institutional investors.

Here is the list of recent funding rounds of Guardian Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2022	6330	Seed	9240	8836	7682	4263

Access funding benchmarks and valuations. Sign up today!

View details of Guardian Bio's funding rounds and investors

The founders of Guardian Bio is Richard Barrett.

Here are the details of Guardian Bio's key team members:

Richard Barrett: Co-Founder and CSO of Guardian Bio.

View details of Guardian Bio's Founder profiles and Board Members

Guardian Bio's employee count trend

Guardian Bio has 3 employees as of Jan 26. Here is Guardian Bio's employee count trend over the years:

Uncover Guardian Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Guardian Bio include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Guardian Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, KKR & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
10th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
1404th	Guardian Bio 2022, Boston (United States), Seed	Developer of cell-therapeutics for the treatment of cancer	$500K	Y Combinator, Phoenix Investment Club & 1 others	35/100